Sei Investments的Johnson & Johnson股份在2025年Q3增加14.7%, Sei Investments increased its Johnson & Johnson stake by 14.7% in Q3 2025 amid strong earnings and FDA approval for a new lens.

Sei Investment Co. 将2025年的Johnson & Johnson股份增加了14.7%,持有152万股,价值2.8190亿美元。 Sei Investments Co. boosted its stake in Johnson & Johnson by 14.7% in Q3 2025, holding 1.52 million shares worth $281.9 million. 该公司报告Q4收入强劲,为246 EPS和242.8亿美元,净利润为28.46%,股本回报率为33.04%。 The company reported strong Q4 earnings of $2.46 EPS and $24.28 billion in revenue, with a 28.46% net margin and 33.04% return on equity. JNJ的股票交易量接近12个月的251.71美元,股息收益为2.1%,年偿付额为5.20美元。 JNJ’s stock traded near its 12-month high of $251.71, with a 2.1% dividend yield and a $5.20 annual payout. 分析师维持了“机动购买”共识,BofA将其目标提高到253美元。 Analysts maintain a "Moderate Buy" consensus, with BofA raising its target to $253. 林业发展局核准了TECNIS Pure see镜头,JNJ正努力扩大欧盟对Tecvayli的标签。 The FDA approved the TECNIS PureSee lens, and JNJ is pursuing EU label expansion for Tecvayli. 内幕人士在90天内出售股票736万美元,包括两名主管将股份减少45.8%。 Insiders sold $7.36 million in shares over 90 days, including two executives reducing stakes by up to 45.8%.